Lilly reports better than expected earnings

6 February 2025

US pharma major Eli Lilly (NYSE: LLY) today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial guidance, with the firm’s shares edging up 1.1% to $843.18.

These revealed that fourth-quarter earnings per share (EPS) were $5.32, $0.02 better than the analyst estimate of $5.30. Revenue for the quarter came in at $13.53 billion versus the consensus estimate of $13.78 billion.

Revenue was driven by volume growth from obesity/diabetes drug tirzepatide, trade names Mounjaro and Zepbound. Non-incretin revenue grew by 20% compared to fourth-quarter 2023.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK